Cerenome Reports First Commercial Diagnostic Revenue and Q3 2026 Financial Results
Cerenome (CNSY) has officially transitioned its CNSide platform from a development phase to commercial operations, reporting $0.7 million in net diagnostic revenue for the third quarter of 2026. The company saw gross billings reach $1.55 million from 222 submitted claims and reported an expansion of its provider network to 45 providers across 26 institutions. While operating losses widened to $7.5 million due to increased commercial team spending, management provided optimistic long-term guidance. The company expects annualized gross billings to reach $10 million–$12.5 million by the end of 2026, with a projected jump to $20 million–$25 million in 2027. Key milestones include expected Medicare reimbursement in the first half of 2027 and the successful closure of Phase II glioblastoma trial enrollment.